Mark Ballantyne

San Francisco – February 9, 2023 – Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.

The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.

Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

Cooley advised the initial purchasers on BigCommerce Holding’s offering of $345 million aggregate principal amount of 0.25% Convertible Senior Notes due 2026. Morgan Stanley, Goldman Sachs and BofA Securities acted as joint book-running managers for the offering. BigCommerce, whose securities trade on the Nasdaq Global Market under the symbol BIGC, is a leading software-as-a-service ecommerce platform. Partners Nicole Brookshire, Mischi a Marca, Jason Savich and Darren Destefano led the Cooley team.

Cooley advised Sensei Biotherapeutics on its $133 million initial public offering of 7,000,052 shares of common stock. Sensei Biotherapeutics, whose securities now trade on the Nasdaq Global Market under the symbol SNSE, is a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer. Partners Michael Tenta, Brian Leaf and Brent Siler led the Cooley team.

Cooley advised Orphazyme on its $83.8 million initial public offering. Orphazyme, whose American depositary shares now trade on the Nasdaq Global Select Market under the symbol ORPH and ordinary shares trade on Nasdaq Copenhagen under the symbol ORPHA, is a Danish late-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of neurodegenerative orphan diseases. Partners Josh Kaufman and Div Gupta and senior associate Mark Ballantyne led the Cooley team.

Cooley advised Legend Biotech on its $487.3 million initial public offering of 21,188,750 American Depository Shares (ADSs). Legend Biotech, whose securities now trade on the Nasdaq Global Select Market under the symbol “LEGN”, is global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Partners Div Gupta, Rob Phillips, Will Cai, Michael Yu and Rich Segal led the Cooley team.